Literature DB >> 12658964

[Concepts in studying cost effectiveness of pediatric asthma treatment in Germany, Switzerland and Austria].

Thomas Frischer1, Felix H Sennhauser, Joachim E Fischer, Thomas Szucs, Christian Köck.   

Abstract

Increasing expenditures of health care systems in industrialised western countries are caused by chronic diseases. Hence, issues on the cost-effectiveness of private as well as public financial resources for asthma therapy in children are gaining importance. In order to study cost-effectiveness issues of defining outcome-measures as well as the reliability and validity of methods to assess these outcomes have to be addressed. Data on direct and indirect costs of asthma have to be gathered. In a first step, comparative costs of asthma therapy of children in Germany, Switzerland and Austria have to be analysed. Subsequently, a randomised, prospective study will be able to demonstrate, whether treatment according to national evidence-based guidelines will be more cost-effective than treatment not taking guidelines into account. Data on the cost-effectiveness of therapy guidelines will help in decision-making of national health care authorities.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12658964     DOI: 10.1046/j.1563-258x.2003.02188.x

Source DB:  PubMed          Journal:  Wien Med Wochenschr        ISSN: 0043-5341


  8 in total

Review 1.  Airway remodeling in asthma. Unanswered questions.

Authors:  J A Elias
Journal:  Am J Respir Crit Care Med       Date:  2000-03       Impact factor: 21.405

2.  Economic costs of disease and injury.

Authors:  S J MUSHKIN; F D COLLINGS
Journal:  Public Health Rep       Date:  1959-09       Impact factor: 2.792

Review 3.  Why does airway inflammation persist? Is it failure to treat early?

Authors:  S Pedersen
Journal:  Am J Respir Crit Care Med       Date:  2000-03       Impact factor: 21.405

4.  Clinical management of asthma in 1999: the Asthma Insights and Reality in Europe (AIRE) study.

Authors:  K F Rabe; P A Vermeire; J B Soriano; W C Maier
Journal:  Eur Respir J       Date:  2000-11       Impact factor: 16.671

5.  A national estimate of the economic costs of asthma.

Authors:  D H Smith; D C Malone; K A Lawson; L J Okamoto; C Battista; W B Saunders
Journal:  Am J Respir Crit Care Med       Date:  1997-09       Impact factor: 21.405

6.  The economic value of human life.

Authors:  D P Rice; B S Cooper
Journal:  Am J Public Health Nations Health       Date:  1967-11

Review 7.  The costs of asthma.

Authors:  P J Barnes; B Jonsson; J B Klim
Journal:  Eur Respir J       Date:  1996-04       Impact factor: 16.671

8.  The economic burden of asthma: direct and indirect costs in Switzerland.

Authors:  T D Szucs; H Anderhub; M Rutishauser
Journal:  Eur Respir J       Date:  1999-02       Impact factor: 16.671

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.